APVO

Aptevo is a pre-revenue, clinical-stage immuno-oncology company whose own 10-K states management and the board 'have concluded that a substantial doubt is deemed to exist concerning our ability to continue as a going concern.' That single disclosure dominates everything else: the company has no product-derived revenue (FY2023–FY2025 revenue is blank in the XBRL, and the last reported figure was a $3.11M contract line back in FY2022, down 74.7% YoY), while net loss has widened every year to -$26.0M in FY2025 and operating cash flow was -$25.6M. Against that burn it held $21.6M of cash at 12/31/2025 — barely one year of runway before the 10-K's mitigations. The accumulated deficit is -$275M, and the -$87.27 diluted EPS reflects how little equity value backs each of the 1.18M shares (a share count that fell 19% YoY, the fingerprint of reverse splits done to stay above Nasdaq's minimums — the filing explicitly flags delisting risk).

The entire equity value is an option on the pipeline: lead asset mipletamig (CD123xCD3 T-cell engager) in the Phase 1b/2 RAINIER trial for frontline AML, plus ALG.APV-527 and six preclinical candidates. Management touts that mipletamig 'continues to outperform standard of care' with 'no cytokine release syndrome' — genuinely encouraging early signal — but its own risk factors concede early data 'may not be predictive of results from later-stage trials' and that serious adverse events could still halt or reverse approval. There is no approved product, no partner-driven revenue beyond contingent IXINITY milestones from Medexus, and success is years and multiple financings away.